<DOC>
	<DOCNO>NCT02809976</DOCNO>
	<brief_summary>The purpose study determine topical ruxolitinib 1.5 % provide repigmentation vitiligo lesion .</brief_summary>
	<brief_title>Topical Ruxolitinib Treatment Vitiligo</brief_title>
	<detailed_description>The hypothesis JAK inhibitor also successfully treat vitiligo . Lesional skin alopecia areata vitiligo primarily contain T cell TH1 response oppose mixed cell infiltrate psoriasis lichen planus . Both alopecia areata vitiligo TH1 mediate disease dependent production IFN-gamma drive response . CD8+ T cell necessary sufficient melanocyte destruction vitiligo ( van den Boorn JG et al 2009 ) CD8+NKG2D+ T cell also necessary sufficient hair loss alopecia areata ( Gilhar A et al 2013 ) .</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<criteria>Clinical diagnosis vitiligo . At Visit 1 ( Baseline/Day 1 ) , vitiligo cover least 1 % total body surface area ( BSA ) scalp , trunk limb ( exclude nail ) . Female subject childbearing potential must agree use highly effective method contraception throughout study least four week last dose assign treatment . Male subject must also use contraception , barrier method spermicide . If receive concomitant medication reason , must stable regimen willing stay stable regimen . Must willing washout vitiligo treatment . All treatment vitiligo prohibit course study . Other skin condition Baseline would interfere evaluation vitiligo . Pregnant/breastfeeding female , female childbearing potential use highly effective contraception . Women childbearing potential must test negative pregnancy use contraception least four week last dose drug . Current recent history clinically significant medical/psychiatric condition laboratory abnormality may increase risk associate study participation drug administration . Have history lymphoproliferative disorder , lymphoma , leukemia , history disseminate herpes zoster disseminate herpes simplex , recurrent localize , dermatomal herpes zoster . Have history infection require parenteral oral topical antimicrobial therapy within 2 week prior Baseline . Vaccinated live/attenuated live vaccine within 6 week prior Baseline . Previously participate study oral/topical ruxolitinib tofacitinib ( tofacitinib , CP690,550 , formerly tasocitinib ) unless confirm randomize treat placebo placebo topical formulation ( vehicle ) . Received prohibited concomitant medication within 7 day 5 halflives ( whichever longer ) prior Baseline . Have participate study within 4 week 5 halflives ( whichever longer ) prior Visit 1 ( Baseline/Day 1 ) . Subjects participate study investigational experimental therapy procedure time participation study . Subjects investigational site staff member relatives site staff member subject Sponsor employee directly involve conduct trial . In opinion investigator Sponsor , subject inappropriate entry study , unwilling/unable comply study procedure lifestyle guideline . Screening laboratory abnormality CYP Inhibitor Exclusion : Subjects take potent CYP3A4 inhibitor fluconazole within 2 week 5 halflives , whichever longer , baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>